We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Waters Corporation Unveils MaxPeak Premier Oligonucleotide Columns

The Waters logo.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Waters Corp introduces its newest MaxPeak Premier Oligonucleotide Columns – now with ethylene bridged hybrid (BEH) particle technology in 300Å wide pore versions – to support applications for nucleic acid therapeutics and cell and gene therapies.

The new columns have all the benefits customers can expect from Waters’ MaxPeak Premier high performance surface chemistry and BEH particle technology – including enhanced sensitivity, reproducibility, and productivity with unmatched pH and temperature stability, which is essential for oligonucleotide/nucleic acid separations. The columns are available for both UPLC separations with Waters’ ACQUITY Premier Oligonucleotide BEH C18 columns and UHPLC/HPLC separations with Waters’ XBridge Premier Oligonucleotide BEH C18 columns.

Oligonucleotide analysis is changing with new modalities demanding more advanced technologies.

New applications associated with nucleic acid therapeutics and vaccines require the ability to separate and analyze long-mer oligonucleotides, which was difficult to achieve with existing column technologies, until now. The Waters MaxPeak Premier Oligonucleotide BEH C18 300Å Columns enable high resolution separation of long-mer oligonucleotides. This means end users developing new gene-based therapeutics – such as mRNA poly(A) tail length and heterogeneity analysis for mRNA therapeutics and vaccines; single guide RNA (sgRNA) characterization for gene editing constructs; and mRNA oligo mapping and sequencing – can more quickly develop analytical methods and characterize the nucleic acid components of these drugs and their impurities.